Plasmid IL-12 electroporation in melanoma

IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.

Interleukin-12 (IL-12) has been used in numerous immunotherapy protocols against melanoma. However, delivery of IL-12 in the form of recombinant protein can result in severe toxicity, and gene therapy has had limited success against B16.F10 murine melanoma. The purpose of this study was to examine the effectiveness of in vivo electroporation for the delivery of plasmid DNA encoding IL-12 as an ...

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

PURPOSE Gene-based immunotherapy for cancer is limited by the lack of safe, efficient, reproducible, and titratable delivery methods. Direct injection of DNA into tissue, although safer than viral vectors, suffers from low gene transfer efficiency. In vivo electroporation, in preclinical models, significantly enhances gene transfer efficiency while retaining the safety advantages of plasmid DNA...

Endogenous IL-12 triggers an antiangiogenic program in melanoma cells.

The IL12RB2 gene acts as a tumor suppressor in human B cell malignancies. Indeed, Il12rb2 knockout (KO) mice develop spontaneously B cell tumors, but also lung epithelial tumors. This latter phenotype may be related to (i) impairment of host IL-12-mediated immunosurveillance and/or (ii) IL-12 inability to inhibit directly the growth of IL-12 unresponsive malignant cells. To address this issue, ...

Broad-Host-Range Plasmid by Electroporation

Methylotrophic bacteria able to grow on one-carbon compounds, such as methanol and monomethylamine, as sole carbon sources have received considerable attention because of their potential commercial applications, including the production of single-cell protein, amino acids, pyrroloquinoline quinone, and poly-3-hydroxybutyrate. The utility of methylotrophs should be increased by the use of recomb...

Eliminating Distal Aggressive Tumors Intramuscular Electroporation Delivery for IL-12 and IL-27 Sequential Gene Therapy via